Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.

Hot Products

China's PI3K Inhibitors Have Made New Progress Since the Approval of Bayer's Copanlisib - Chiatai Tianqing's TQ-B3525 Is Proposed to Be Included in the Priority Review

Dopine/PharmaSourcesJune 06, 2023

Tag: TQ-B3525 , Follicular lymphoma , PI3K inhibitor